Bayer Faces Triple Pressure: A Trade Probe, a Roundup Deadline, and a Supreme Court Watch
20.06.2026 - 12:01:46 | boerse-global.de
Bayer’s stock ended the week pinned to its 50-day moving average at €37.80, a technical standstill that masks the convergence of three high-stakes events now bearing down on the German pharmaceutical and life-sciences group. The shares have rallied roughly 41% over the past twelve months, but investors are weighing whether that run can survive the political, legal, and commercial crosscurrents of the coming months.
US Tariffs Loom Over Drug Pricing
Washington has opened a formal investigation into German drug-pricing practices under the Trade Act, targeting what US Trade Representative Jamieson Greer has called “unfair” price controls on innovative medicines. The probe alleges that Berlin’s strict price regulations force American consumers to shoulder a disproportionate share of global research and development costs. In a worst-case scenario, the US could slap punitive tariffs on German pharmaceutical exports, hitting Bayer and other export-heavy German drugmakers directly.
The timetable is set. A public comment period opens on June 25, 2026, written submissions are due by August 10, and a public hearing in the US will follow on September 22. Compounding the risk, Washington is monitoring Berlin’s proposed GKV savings package, which aims to cut domestic healthcare spending. For Bayer, that means pressure on both sides of the Atlantic: lower revenues in Germany from price curbs and potential tariffs on its sizeable North American business.
Roundup: A Settlement Hearing Nears While the Supreme Court Looms
On the litigation front, Bayer secured a procedural victory on June 17 when US District Judge Henry E. Autrey in the Eastern District of Missouri ruled that the King v. Monsanto class-action settlement belongs in Missouri state court, not federal court. The judge rejected arguments from a group of cancer victims who claimed a state court could not bind a nationwide class. Crucially, Autrey noted that only Bayer as the defendant could have moved the case to federal court — the plaintiffs could not. The ruling removes Judge Stephen R. Clark, who had publicly criticised the settlement, from the picture.
Should investors sell immediately? Or is it worth buying Bayer?
The case now returns to Judge Timothy Boyer in St. Louis, who gave preliminary approval to the settlement in March. The final fairness hearing is set for July 9, 2026. Dissenting plaintiffs have already appealed Autrey’s decision, adding an element of uncertainty to the timeline.
Simultaneously, Bayer is awaiting a US Supreme Court ruling, expected by the end of July, on whether federal pesticide regulations preempt state-law claims about inadequate warning labels. That decision could redefine the entire Roundup litigation landscape.
Bayer has already spent over $10 billion to resolve Roundup claims, with roughly 65,000 outstanding cases. The February 2026 settlement proposal aims to end nearly all remaining litigation through a new class mechanism. The cost of litigation is heavy: management forecasts about €5 billion in legal cash outflows for 2026 alone, pushing free cash flow into negative territory as low as minus €2.5 billion.
Bayer at a turning point? This analysis reveals what investors need to know now.
Perfuse Acquisition Closes, Adding Pipeline Depth
Also on June 17, Bayer announced the completion of its acquisition of Perfuse Therapeutics. The deal includes an upfront payment of $300 million, with milestone payments that could lift the total consideration to $2.45 billion. The centrepiece is PER-001, an intravitreal implant with sustained drug release that is currently in Phase II trials for glaucoma and diabetic retinopathy — conditions affecting up to 80 million and roughly 146 million people worldwide, respectively. Bayer sees PER-001 as a potential first-in-class disease-modifying therapy for both indications, providing a long-term pipeline catalyst that could offset pricing pressure in its established pharmaceutical portfolio.
The Calendar That Will Define the Next Move
Bayer’s stock closed at €37.81 in Friday trading, up roughly 2% on the day and nearly 5% for the week — exactly on its 50-day moving average. The technical picture is neutral, and the direction will likely be set by the events now stacked on the calendar: the July 9 settlement hearing in St. Louis, the Supreme Court ruling by end-July, and the US trade investigation’s September hearing. Any one of the three could tip the balance for a stock that has rallied hard from its 12-month lows but now faces a trio of defining moments.
Ad
Bayer Stock: New Analysis - 20 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
